PTGER4 and colorectal carcinoma: Accordingly, several interventional clinical phase-1 studies with focus on CRC have been initiated with newly developed EP4 antagonists [31], and recently another trial, testing an EP4 antagonist in metastatic CRC patients, has proceeded to phase II (NCT05205330).